艾可寧
?核心期刊發(fā)表文章
1.Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, Huang M, Chen B, Liu B, Li X, Jiang H. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother. 2010 Jan;54(1):191-6.
2.Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One. 2012;7(3):e32599. doi:10.1371/journal.pone.0032599.
3.Wu H, Yao C, Lu R, et al. Albuvirtide, the first long-acting HIV-1 fusion inhibitor, suppressed viral replication in HIV infected adults: the Interscience Conference on Antimicrobial Agents and Chemotherapy. [R]. San Francisco: [s.n.], 2012.
4.Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, Peng H, Wang X, Lu R, Wang C, Xie D, Wu H. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016 Feb 10;13:8.?doi: 10.1186/s12981-016-0091-1.
5.Yang W, Xiao Q, Wang D, Yao C, Yang J. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results. Xenobiotica.2017 Feb;47(2):133-143.
6.謝東. 抗艾滋病藥物研發(fā)新策略 [J]. 藥學(xué)進展. 2018, 42 (2): 81-83.
7.姚成，朱盼盼，謝東. 艾滋病抗病毒治療及藥物研究進展 [J]. 藥學(xué)進展. 2018, 42 (2): 84-98.
8.Yang J, Wei G, He Y, Hua X, Feng S, Zhao Y, Chen T, Wang H, Guo L. Perioperative Antiretroviral Regimen for HIV/AIDS Patients Who Underwent Abdominal Surgery. World J Surg. 2020 Jun;44(6):1790-1797.
9.Nie J, Sun F, He X, Liu J, Wang M, Li C, Gu S, Chen Z, Li Y, Chen Y. Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China. Infect Dis Ther. 2021 Dec;10(4):2611-2623.
10.Su B, Yao C, Zhao QX, et al. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. J Infect. 2022 Sep;85(3):334-363.
11.Yang J, Wei G, Gui F, Zhao Y, Chen T, Tan J. Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer. AIDS Res Ther. 2022 Sep 23;19(1):45.
12.Chen L, Dai H, Wang J, Wang M, Ma Y, Ma F, Li C, Bai L, Du L, Tang H. Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study. Ann Transl Med. 2022 Oct;10(20):1125.
13.Tang W, Song XY, Cao J, Liu C, Zheng F. Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report. AIDS Res Ther. 2023 Aug 28;20(1):60
14.Liu H, He S, Yang T, Lu C, Yao Y, Zhou R, Yin K, He Y, Cheng J. Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS. Medicine (Baltimore). 2023 Nov 10;102(45):e35344.
15.Qin H, Yao C, Zhang W, Hu W, Liu Y, Yu S, Xie D, Hu M, Ye J. Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection. Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):913-922.?
16.Chen Z, Si T, Ying L, Guiying C, Píng XJ, Wang M. A case of multiple ART intolerance responds to Albuvirtide and Dolutegravir: Case report and literature review. Heliyon. 2024 Mar 12;10(6):e27219.
17.Fan L, Hu Y, Li R, Ding J, Liu Y, Yu S, Hu M, Su R, Li Y, Yu A, Xie D, Zhao Q, Ma P. Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders. Front Cell Infect Microbiol. 2024 Jun 21;14:1397743.
18.Li N, Wen S, Zhu F, Liu G, Zhu D. Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report. BMC Pregnancy Childbirth. 2025 Jan 23;25(1):61.?
19.Xie X, Fu Y, Gan L, Yang X, Song Y, Song C, Sun F, Guo L, Long H. Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study. AIDS. 2025 Jan 27.?Epub ahead of print.?